AOD-9604

Published · Researched 2026-09-21

1. Overview

  • Maker: Originally developed by Metabolic Pharmaceuticals (Australia) — company wound down after the obesity program failed in Feb 2007; the molecule was later picked up by Calzada Limited (who also took it into osteoarthritis trials as "AOD-9604"/"AOD9604"). There is no original brand owner active in 2026; the compound survives only as a research-chemical sold by independent peptide vendors.
  • Purpose: 16-amino-acid fragment of human growth hormone (hGH fragment 176–191, with one amino acid modified vs. the native fragment). Marketed by vendors as a "fat-burning peptide" that stimulates lipolysis via beta-3 adrenergic receptor signaling without raising IGF-1 or impairing glucose tolerance.
  • Current 2026 version: Research chemical, lyophilized powder in 2/5/10 mg vials. Also briefly sold in oral/liquid forms; injectable is the community standard. Sold for research use only — no brand, no drug product.

2. Social standing

  • Platform pulse: High name recognition, low respect. AOD-9604 is one of the most-mentioned "fat loss peptides" in gray-market chatter, but among informed peptide communities it is the "frustrating" classic: constant discussion, mostly complaints about efficacy and reconstitution.
  • Facebook group consensus: No posts mentioning AOD-9604 found in the two public peptide Facebook groups searched via facebook-cli (Sept 2026).
  • Viral moments: TikTok creator @barrythebiooptimizer (TikTok, post with 1,068 likes / 197 comments, circa early 2026): "AOD-9604: The most frustrating fat loss peptide? … 30–50% of people get ZERO results. Why? Your beta-3 receptor genetics determine if you're a responder. … The real nightmare? Reconstitution. This peptide LOVES turning into useless gel. Too cold? Gel. Wrong pH? Gel. Look at it wrong? Gel." — flagged as one of the clearest community summaries of the compound's reputation.
  • Praise: Users who report success cite stubborn-fat loss over 8–12 week cycles with no appetite suppression or hormonal disruption; vocal.media review aggregation quotes u/TestosteroneFan (Reddit r/Peptides): 5/5 combining AOD-9604 with TRT for two months, "fat loss is noticeable, and my muscle mass is staying intact." Brainflow (Jul 2026): users report early changes around week 4–6 of an 8–12 week cycle, praising tolerability, no muscle loss, low cost.
  • Complaints: Dominant theme. Threads user @shellamariie (Jul 17, 2026) asked for thoughts on the peptide; comments: "hirap i recon. prone sa gelling" (hard to reconstitute, prone to gelling) — @MC GLOW. Others echo "gelling" complaints. u/GymShark (Bodybuilding.com, via vocal.media): oral form gave no significant fat loss, injectable better. u/StruggleToFit (Reddit r/WeightLoss): a month in, "minimal results," more energy only. TikTok: 30–50% get zero results. Skeptic blogs (undergroundbiohacking.com, primelabpeptides.com) stress that the 24-week Phase 2b (534 subjects) showed no meaningful separation from placebo and was never peer-reviewed — vendors citing "successful trials" are recycling a 2004 press release.
  • Verified quotes (paraphrased, attributed):
    • Threads @MC GLOW (Jul 2026): AOD is a "T booster for weightloss, effective pero hirap i recon. prone sa gelling." — platform: Threads.
    • TikTok @barrythebiooptimizer: "This peptide LOVES turning into useless gel. Too cold? Gel. Wrong pH? Gel. Look at it wrong? Gel." — platform: TikTok (cross-platform creator content, discovered via web search).
    • Threads seller "Jinnn" (Jul 2026): "i have AOD, dear! 📩📩" — platform: Threads (illustrates gray-market DM sales culture; not an efficacy claim).
    • undergroundbiohacking.com (Sept 2026): community protocol 250–500 mcg/day subcutaneous, fasted, 8–12 week cycles with 4–6 week breaks; frames it as research framework, not prescription.

3. Social validation — Tier 3 (weak)

  • Tier 3 — flagged as weak. Real user/owner voices exist (Threads comment thread, Reddit-sourced reviews, TikTok creator), but all on a single target platform family (Threads) plus non-contract platforms (TikTok, Reddit/forum aggregates). No Facebook Groups presence, no IG owner content found.
  • Named sources and what each proves:
    1. Threads @shellamariie post "LF: AOD 9604 📍QC" (Jul 17, 2026, 5 comments) — proves active buyer interest and the gelling/reconstitution complaint among actual users; includes a gray-market seller pitch, proving how sourcing happens.
    2. Threads @deartylabee clinical-scientist peptide explainer (Apr 2026, 21 replies) — proves professional/educational layer around AOD-9604 in the Threads ecosystem.
    3. TikTok @barrythebiooptimizer (1,068 likes, 197 comments) — proves creator-layer consensus: "most frustrating fat loss peptide," responder genetics, reconstitution nightmare.
    4. vocal.media review aggregation (2026) — proves continued user-experience corpus on Reddit/forums (r/Peptides, r/WeightLoss, Bodybuilding.com), mixed results.
    5. Searched but empty: Facebook group post queries for "AOD-9604" (Sept 2026), IG following-feed content.

4. Key specs table

Spec Detail Source
Mechanism hGH fragment 176–191 analogue; stimulates lipolysis via beta-3 adrenergic receptor; no GH-receptor binding, no IGF-1 elevation paragonssportsmedicine.com; fitscience.co
Half-life ~4 minutes plasma (IV); oral dosing used in human trials; SC bioavailability/kinetics in community use UNVERIFIED paragonssportsmedicine.com
Dosing schedule Trials: 0.25–1 mg daily (oral). Community: 250–500 mcg/day subcutaneous, fasted AM and/or pre-cardio, 8–12 week cycles with 4–6 week breaks fitscience.co; undergroundbiohacking.com
Administration route Injectable (subcutaneous) in gray-market use; oral in trials —
Trial phase Program discontinued Feb 2007 after failed 24-week Phase 2b (n≈534, no separation from placebo). Six human studies 2001–2006; 12-week trial (n=300): ~2 kg fat-mass edge vs placebo (2.6 vs 0.8 kg weight loss per paragonssportsmedicine). Only safety arm of Phase 2b peer-reviewed (2013) primelabpeptides.com; paragonssportsmedicine.com
Measured efficacy Best human signal: ~2 kg placebo-adjusted weight loss at 12 weeks (best dose); 24-week Phase 2b: no meaningful separation. Animal: up to 50% increased lipolytic activity vs control fitscience.co; primelabpeptides.com

5. Pricing (dated 2026-09-20)

  • Current MSRP (brand): None — no brand, no approved drug product. Not compoundable (FDA Category 2 as of 2026 per brainflow.co) and never FDA approved; GRAS food-ingredient status is not drug approval.
  • Street price (research/compounded): $49.99 for a 5 mg vial at Amino Club (with code BRAINFLOW, 20% off) — cited by brainflow.co, July 2026. Typical vendor range UNVERIFIED beyond this single sourced figure.
  • Marketplace used range: None observed; Facebook Marketplace search not returned in this pass — flagged UNVERIFIED.

6. What is included / what else is needed

  • Included: Lyophilized powder vial (2/5/10 mg from typical vendors).
  • Also needed: Bacteriostatic water (typical: 2 mL per 5 mg vial per fitscience.co), insulin syringes, alcohol swabs; acetic acid sometimes suggested for reconstitution given gelling issues. Research chemical not for human use.

7. Support reality

  • Brand: N/A — no manufacturer, no warranty.
  • Gray-market: Vendor-dependent, typically no returns on research chemicals. Amino Club-style 7× batch testing with COAs is cited as the community's quality proxy, but that claim is vendor marketing — treat as such.

8. Community verdict

AOD-9604 is the peptide world's cautionary classic: one of the most talked-about fat-loss peptides, yet the conversation skews heavily toward frustration — half the users see little, reconstitution is a running joke ("look at it wrong? gel"), and the actual human trial program failed. Its niche defenders keep it alive for stubborn-fat cycles alongside a GLP-1, with no appetite sides and low cost, but honest community voices rate it a gamble, not a workhorse.

9. Regulatory & safety status

  • Research chemical — NOT FDA/EMA approved as a drug. AOD-9604 never received drug approval anywhere. It holds GRAS (Generally Recognized As Safe) status as a food ingredient — that is a food-safety category, not drug approval, and the two are constantly conflated by vendors. Per brainflow.co (July 2026), as of 2026 it sits in FDA Category 2, so US pharmacies cannot legally compound it. WADA-prohibited since ~2013 (S0 non-approved substance). Australia TGA: Schedule 4.
  • Known safety signals: Across 900+ human trial participants: no serious adverse events attributed; no IGF-1 elevation; no glucose-tolerance impairment. Common complaint is injection-site irritation; no trials on long-term use. FDA has flagged limited safety information for compounded versions (per Medium review, 2026).

10. Missing-image views + UNVERIFIED points log

  • Images found (3/8): hero (Peptide Pure 5 mg vial product photo, peptidepure.com), side (Edge Peptides 5 mg vial product photo, edgepeptides.com), detail (10 mg "Research purposes only" vial photo, pepessentials.com via cloudfront). All retailer product photography; no owner photos. Missing: rear, top, owner-in-use, scale, box/accessories.
  • UNVERIFIED:
    1. Exact SC half-life / pharmacokinetics in community dosing — only the ~4-min IV plasma figure is sourced.
    2. Facebook Marketplace used range — not observed.
    3. Typical vendor price range beyond the single Amino Club figure.
    4. 30–50% "zero responder" genetics claim — creator assertion (TikTok), no sourced trial basis.
    5. Vendor purity claims (e.g., 7× testing, 99%+) — marketing, not independently verified.
    6. 2.6 vs 0.8 kg figure — attributed to paragonssportsmedicine.com summary; primary trial paper not fetched.
    7. "FDA Category 2" 2026 status — cited by brainflow.co only; not independently confirmed.

Not medical advice. This is research material only; consult a qualified clinician.

AOD-9604 — detail view
detail view Original vendor page URL not recorded in research dossier
AOD-9604 — hero view
hero view Original vendor page URL not recorded in research dossier
AOD-9604 — side view
side view Original vendor page URL not recorded in research dossier

Named sources

  • Threads @shellamariie post "LF: AOD 9604 📍QC" (Jul 17, 2026, 5 comments) — proves active buyer interest and the gelling/reconstitution complaint among actual users (Jul 17, 2026)
  • Threads @deartylabee clinical-scientist peptide explainer (Apr 2026, 21 replies) — proves professional/educational layer around AOD-9604 in the Threads ecosystem. (Apr 2026)
  • TikTok @barrythebiooptimizer (1,068 likes, 197 comments) — proves creator-layer consensus: "most frustrating fat loss peptide," responder genetics, reconstitution nightmare.
  • vocal.media review aggregation (2026) — proves continued user-experience corpus on Reddit/forums (r/Peptides, r/WeightLoss, Bodybuilding.com), mixed results. (2026)
  • paragonssportsmedicine.com — Mechanism: hGH fragment 176–191 analogue; stimulates lipolysis via beta-3 adrenergic receptor; no GH-receptor binding, no IGF-1 elevation
  • fitscience.co — Measured efficacy: Best human signal: ~2 kg placebo-adjusted weight loss at 12 weeks (best dose); 24-week Phase 2b: no meaningful separation.
  • undergroundbiohacking.com — Dosing schedule: Trials: 0.25–1 mg daily (oral).
  • primelabpeptides.com — Measured efficacy: Best human signal: ~2 kg placebo-adjusted weight loss at 12 weeks (best dose); 24-week Phase 2b: no meaningful separation.
  • @MC GLOW — prone sa gelling" (hard to reconstitute, prone to gelling) — @MC GLOW.
  • Reddit u/TestosteroneFan — Users who report success cite stubborn-fat loss over 8–12 week cycles with no appetite suppression or hormonal disruption; vocal.media review aggregation quotes u/TestosteroneFan (Reddit r/Peptides): 5/5 combining AOD-9604 with TRT for two months, "fat loss…
  • Reddit u/GymShark — u/GymShark (Bodybuilding.com, via vocal.media): oral form gave no significant fat loss, injectable better.
  • Reddit u/StruggleToFit — u/StruggleToFit (Reddit r/WeightLoss): a month in, "minimal results," more energy only.
  • brainflow.co — Not compoundable (FDA Category 2 as of 2026 per brainflow.co) and never FDA approved; GRAS food-ingredient status is not drug approval. (2026)
  • Skeptic blog — Skeptic blogs (undergroundbiohacking.com, primelabpeptides.com) stress that the 24-week Phase 2b (534 subjects) showed no meaningful separation from placebo and was never peer-reviewed — vendors citing "successful trials" are recycling a 2004 press release. (2004)
  • Reddit-sourced review — **Tier 3 — flagged as weak.** Real user/owner voices exist (Threads comment thread, Reddit-sourced reviews, TikTok creator), but all on a single target platform family (Threads) plus non-contract platforms (TikTok, Reddit/forum aggregates).
  • Medium review — FDA has flagged limited safety information for compounded versions (per Medium review, 2026). (2026)

Source URLs were not recorded for these references.